Literature DB >> 28148583

ANCA-associated vasculitis.

Max Yates1, Richard Watts2.   

Abstract

The vasculitides are a heterogeneous group of conditions typified by their ability to cause vessel inflammation with or without necrosis. They present with a wide variety of signs and symptoms and, if left untreated, carry a significant burden of mortality and morbidity. The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are three separate conditions - granulomatosis with polyangiitis (GPA; formerly known as Wegener's granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg-Strauss syndrome). This review examines recent developments in the pathogenesis and treatment of AAV, focusing on developments in treatment following the introduction of rituximab, in particular. © Royal College of Physicians 2017. All rights reserved.

Entities:  

Keywords:  ANCA; diagnosis; rituximab; treatment; vasculitis

Mesh：

Substances：

Year:  2017        PMID： 28148583      PMCID： PMC6297586          DOI： 10.7861/clinmedicine.17-1-60

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


  20 in total

1.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Rona M Smith; Rachel B Jones; Mary-Jane Guerry; Simona Laurino; Fausta Catapano; Afzal Chaudhry; Kenneth G C Smith; David R W Jayne
Journal:  Arthritis Rheum       Date:  2012-11

Review 4.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors:  Bernhard Hellmich; Oliver Flossmann; Wolfgang L Gross; Paul Bacon; Jan Willem Cohen-Tervaert; Loic Guillevin; David Jayne; Alfred Mahr; Peter A Merkel; Heiner Raspe; David G I Scott; James Witter; Hasan Yazici; Raashid A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

5.  A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Rachel B Jones; Alastair J Ferraro; Afzal N Chaudhry; Paul Brogan; Alan D Salama; Kenneth G C Smith; Caroline O S Savage; David R W Jayne
Journal:  Arthritis Rheum       Date:  2009-07

6.  Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

Authors:  Lorraine Harper; Matthew D Morgan; Michael Walsh; Peter Hoglund; Kerstin Westman; Oliver Flossmann; Vladimir Tesar; Phillipe Vanhille; Kirsten de Groot; Raashid Luqmani; Luis Felipe Flores-Suarez; Richard Watts; Charles Pusey; Annette Bruchfeld; Niels Rasmussen; Daniel Blockmans; Caroline O Savage; David Jayne
Journal:  Ann Rheum Dis       Date:  2011-11-29       Impact factor: 19.103

7.  Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Kirsten De Groot; Niels Rasmussen; Paul A Bacon; Jan Willem Cohen Tervaert; Conleth Feighery; Gina Gregorini; Wolfgang L Gross; Raashid Luqmani; David R W Jayne
Journal:  Arthritis Rheum       Date:  2005-08

8.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

9.  Modification and validation of the Birmingham Vasculitis Activity Score (version 3).

Authors:  C Mukhtyar; R Lee; D Brown; D Carruthers; B Dasgupta; S Dubey; O Flossmann; C Hall; J Hollywood; D Jayne; R Jones; P Lanyon; A Muir; D Scott; L Young; R A Luqmani
Journal:  Ann Rheum Dis       Date:  2008-12-03       Impact factor: 19.103

10.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01
View more
  48 in total

1.  [A rare manifestation of an inflammatory rheumatic systemic disease].

Authors:  Ole Hudowenz; Malte Knabe; Kirsten de Groot
Journal:  Z Rheumatol       Date:  2018-10       Impact factor: 1.372

Review 2.  ANCA Glomerulonephritis and Vasculitis.

Authors:  J Charles Jennette; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2017-08-25       Impact factor: 8.237

3.  Consequences of cathepsin C inactivation for membrane exposure of proteinase 3, the target antigen in autoimmune vasculitis.

Authors:  Seda Seren; Maha Rashed Abouzaid; Claudia Eulenberg-Gustavus; Josefine Hirschfeld; Hala Nasr Soliman; Uwe Jerke; Koffi N'Guessan; Sandrine Dallet-Choisy; Adam Lesner; Conni Lauritzen; Beate Schacher; Peter Eickholz; Nikoletta Nagy; Marta Szell; Cécile Croix; Marie-Claude Viaud-Massuard; Abdullah Al Farraj Aldosari; Shivanna Ragunatha; Mostafa Ibrahim Mostafa; Francesca Giampieri; Maurizio Battino; Hélène Cornillier; Gérard Lorette; Jean-Louis Stephan; Cyril Goizet; John Pedersen; Francis Gauthier; Dieter E Jenne; Sylvain Marchand-Adam; Iain L Chapple; Ralph Kettritz; Brice Korkmaz
Journal:  J Biol Chem       Date:  2018-06-20       Impact factor: 5.157

4.  ANCA-associated vasculitis and severe proximal muscle weakness.

Authors:  Jordan S Dutcher; Albert Bui; Tochukwu A Ibe; Goyal Umadat; Eugene P Harper; Erik H Middlebrooks; Michael M Mohseni; Michael B Phillips
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-01-14

5.  Long-Term Prognostic Factors in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A 15-Year Multicenter Retrospective Study.

Authors:  Qian-Qian Liao; Ya-Fei Ren; Ke-Wei Zhu; Dong Qin; Yan-Ju Mo; Shan Cong; Juan Wu; Chun-Ying Wang; Xiao-Jiao Cui; Hong-Zhen Xu; Lin-Zheng Guo; You-Yan Zhang; Hai-Xia Song; Wei Zhang; Zhe Yang; Yan-Feng Tang; Zhuo-Jun Li; Zhou-Ni Xie; Li-Mei Li; Hui-Juan Wang; Meng-Meng Zhou; Fang-Ning Wei; Peng Chen; Yu-Hong Shi
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

6.  Serum albumin, prealbumin, and ischemia-modified albumin levels in patients with ANCA-associated vasculitis: A prospective cohort study.

Authors:  Sung Soo Ahn; Taejun Yoon; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  PLoS One       Date:  2022-07-07       Impact factor: 3.752

7.  Alterations in circulating lymphoid cell populations in systemic small vessel vasculitis are non-specific manifestations of renal injury.

Authors:  B Fazekas; A Moreno-Olivera; Y Kelly; P O'Hara; S Murray; A Kennedy; N Conlon; J Scott; A M Melo; F B Hickey; D Dooley; E C O'Brien; S Moran; D G Doherty; M A Little
Journal:  Clin Exp Immunol       Date:  2017-10-20       Impact factor: 4.330

8.  ANCA-Associated Vasculitis Clinical Presentation and Clinical Predictors of Relapse in Saudi Arabia.

Authors:  Hana Alahmari; Hana Al Daajani; Fatimah Alsayed; Abdulrhaman Alrashid
Journal:  Open Access Rheumatol       Date:  2021-07-17

Review 9.  Cardiac imaging of a patient with unusual presentation of granulomatosis with polyangiitis: A case report and review of the literature.

Authors:  Rabah Al-Mehisen; Khalid Alnemri; Maha Al-Mohaissen
Journal:  J Nucl Cardiol       Date:  2019-07-26       Impact factor: 5.952

Review 10.  Proposal for a more practical classification of antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Nestor Oliva-Damaso; Andrew S Bomback
Journal:  Clin Kidney J       Date:  2020-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.